scholarly journals Pharmacological and Neuroprotective Natural Products in the Treatment of Alzheimer’s Disease

2021 ◽  
Vol 6 (3) ◽  
pp. 366-382
Author(s):  
A.Mary Prashanthi ◽  
Vissarapu Naga Lakshmi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Natural Products ◽  
Drug Discovery ◽  
Medical Condition ◽  
Local Area ◽  
Clinical Use ◽  
Pharmacological Agents ◽  
New Methodologies ◽  
Wide Assortment

Alzheimer's illness (AD) is a progressive, neurodegenerative issue and has become an incredible medical condition especially among the old individuals, for the most part happens after the age of 55 years and expansion in frequency with propelling age, however its therapy alternatives are generally not many and inadequate. The reason for AD isn't actually known, yet is thought to incorporate both hereditary and natural elements (multifactorial). There is no known remedy for Alzheimer's sickness, since it is beyond the realm of imagination to expect to invert the demise of synapses however the indications can be overseen by some pharmacological specialists and Neuroprotective Natural Products. In spite of the improvement of various pharmacological methodologies throughout the years pointed toward treating Alzheimer's Disease (AD) without a doubt, not many have been supported for clinical use in patients. To date there still exists no illness adjusting treatment that could forestall or protect the intellectual debilitation, especially of memory aquisition, that is normal for AD. One of the opportunities for this situation may be that most of medication disclosure endeavors centers around result proportions of diminished neuropathological biomarkers normal for AD, without taking into acount neuronal cycles fundamental for the age and support of memory measures. In endeavors to find new methodologies for AD treatment, regular items have stirred interest in the examination local area and in the drug business for their neuroprotective movement, focusing on various obsessive instruments related with AD. A wide assortment of normal items from various beginnings have been assessed preclinically and clinically for their neuroprotective instruments in forestalling and lessening the multifactorial pathologies of AD. It is accepted that normal item blends or concentrates containing different bioactive mixtures that can work additively or synergistically to display various neuroprotective systems may be a compelling methodology in AD drug discovery. Keywords: Alzheimer’s disease (AD); neurodegenerative disease, natural products, pharmacological agents.

Alzheimer's disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes

2014 ◽  
Vol 15 ◽  
pp. 116-145 ◽  
Author(s):  
Tiago Silva ◽  
Joana Reis ◽  
José Teixeira ◽  
Fernanda Borges
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Natural Products ◽  
Drug Discovery

scholarly journals Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease

2020 ◽  
Vol 13 (9) ◽  
pp. 242
Author(s):  
Márcia Martins ◽  
Renata Silva ◽  
Madalena M. M. Pinto ◽  
Emília Sousa
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Natural Products ◽  
Marine Natural Products ◽  
Biological Activities ◽  
Drug Repurposing ◽  
Phase Iii ◽  
Pharmacological Agents ◽  
Chemical Structures

Alzheimer’s disease (AD) is a multifactorial disease characterized by the presence of amyloid plaques, neurofibrillary tangles, and nerve cell death that affects, mainly, older people. After decades of investigation, the search for an efficacious treatment for AD remains and several strategies can be and are being employed in this journey. In this review, four of the most promising strategies, alongside with its most promising agents under investigation or development are highlighted. Marine natural products (MNP) are a source of unique chemical structures with useful biological activities for AD treatment. One of the most promising compounds, a marine-derived acidic oligosaccharide (GV-971) just passed phase III clinical trials with a unique mechanism of action. Combination therapy and multitargeted-directed ligand therapy (MTDL) are also two important strategies, with several examples in clinical trials, based on the belief that the best approach for AD is a therapy capable of modulating multiple target pathways. Drug repurposing, a strategy that requires a smaller investment and is less time consuming, is emerging as a strong contender with a variety of pharmacological agents resurfacing in an attempt to identify a therapeutic candidate capable of modifying the course of this disease.

Natural Anti-inflammatory compounds as Drug candidates in Alzheimer’s disease

2020 ◽  
Vol 27 ◽  
Author(s):  
Reyaz Hassan Mir ◽  
Abdul Jalil Shah ◽  
Roohi Mohi-ud-din ◽  
Faheem Hyder Potoo ◽  
Mohd. Akbar Dar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Natural Products ◽  
Protective Action ◽  
New Drugs ◽  
Huperzine A ◽  
Brain Disorder ◽  
Anti Inflammatory

: Alzheimer's disease (AD) is a chronic neurodegenerative brain disorder characterized by memory impairment, dementia, oxidative stress in elderly people. Currently, only a few drugs are available in the market with various adverse effects. So to develop new drugs with protective action against the disease, research is turning to the identification of plant products as a remedy. Natural compounds with anti-inflammatory activity could be good candidates for developing effective therapeutic strategies. Phytochemicals including Curcumin, Resveratrol, Quercetin, Huperzine-A, Rosmarinic acid, genistein, obovatol, and Oxyresvertarol were reported molecules for the treatment of AD. Several alkaloids such as galantamine, oridonin, glaucocalyxin B, tetrandrine, berberine, anatabine have been shown anti-inflammatory effects in AD models in vitro as well as in-vivo. In conclusion, natural products from plants represent interesting candidates for the treatment of AD. This review highlights the potential of specific compounds from natural products along with their synthetic derivatives to counteract AD in the CNS.

An Insight in Pathophysiological Mechanism of Alzheimer’s Disease and its Management using Plant Natural Products

2020 ◽  
Vol 20 ◽  
Author(s):  
Zeba Firdaus ◽  
Tryambak Deo Singh
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Natural Products ◽  
Side Effects ◽  
Neuronal Degeneration ◽  
Acetylcholinesterase Inhibitor ◽  
Pathophysiological Mechanism ◽  
Limited Effectiveness ◽  
Drug Development Research ◽  
Sites Of Action

: Alzheimer’s disease (AD) is an age-associated nervous system disorder and a leading cause of dementia worldwide. Clinically it is described by cognitive impairment, and pathophysiologically by deposition of amyloid plaques and neurofibrillary tangles in the brain and neurodegeneration. This article reviews the pathophysiology, course of neuronal degeneration, and the various possible hypothesis of AD progression. These hypotheses include amyloid cascade, tau hyperphosphorylation, cholinergic disruption, metal dysregulation, vascular dysfunction, oxidative stress, and neuroinflammation. There is an exponential increase in the occurrence of the AD in recent few years that indicate an urgent need to develop some effective treatment. Currently, only 2 classes of drugs are available for AD treatment namely acetylcholinesterase inhibitor and NMDA receptor antagonist. Since AD is a complex neurological disorder and these drugs use a single target approach, alternatives are needed due to limited effectiveness and unpleasant side-effects of these drugs. Currently, plants have been used for drug development research especially because of their multiple sites of action and fewer side effects. Uses of some herbs and phytoconstituents for the management of neuronal disorders like AD have been documented in this article. Phytochemical screening of these plants shows the presence of many beneficial constituents like flavonoids, triterpenes, alkaloids, sterols, polyphenols, and tannins. These compounds show a wide array of pharmacological activities such as anti-amyloidogenic, anticholinesterase, and antioxidant. This article summarizes the present understanding of AD progression and gathers biochemical evidence from various works on natural products that can be useful in the management of this disease.

Pharmacophore Modeling and Docking Studies to Investigate Potential Leads for the Development of β -Secretase APP Cleavage Enzyme-1 (BACE-1) Inhibitors

2019 ◽  
Vol 16 (7) ◽  
pp. 775-784
Author(s):  
Richa Arya ◽  
Satya Prakash Gupta ◽  
Sarvesh Paliwal ◽  
Swapnil Sharma ◽  
Kirtika Madan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Medical Condition ◽  
Pharmacophore Model ◽  
Pharmacophore Modeling ◽  
Docking Studies ◽  
Pyridine Derivative ◽  
Cleavage Enzyme ◽  
Bace 1

Background: Alzheimer’s disease is a medical condition with detrimental brain health. It is majorly diagnosed in aging individuals plaque in β) characterized by accumulated Amyloidal beta (A 1 BACE) 1 secretase APP cleavage enzyme βneurological areas. The ) is the target of choice that can be exploited to find drugs against Alzheimer’s disease. Methods: A series of BACE-1 inhibitors with reported binding constant were considered for the development of a feature based pharmacophore model. Results: The good correlation coefficient (r=0.91) and RMSD of 0.93 was observed with 30 compounds in training set. The model was validated internally (r2test=0.76) as well as externally by Fischer validation. The pharmacophore based virtual screening retrieved compounds that were docked and biologically evaluated. Conclusion: The three structurally diverse molecules were tested by in-vitro method. The pyridine derivative with highest fit value (6.9) exhibited IC50 value of 2.70 µM and thus was found to be the most promising lead molecule as BACE-1 inhibitor.

Sign in / Sign up

Export Citation Format

Share Document